12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

PreFluCel influenza vaccine regulatory update

EMA's CHMP recommended updating the marketing approval for Baxter's PerFluCel influenza vaccine to include changes to the manufacturing process after Baxter voluntarily recalled batches of the product in October due to reports of serious adverse events, including cases of anaphylactic reactions, influenza-like symptoms and eye...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >